Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Intra-Cellular Therapies Inc. researches and develops biopharmaceutical drugs. The Company engages in the research and development of small molecule drugs to treat neuropsychiatric and neurological diseases and other disorders of the central nervous system. Intra-Cellular Therapies offers its products to the medical industry.
Website: intracellulartherapies.com



Growth: Good revenue growth rate 50.8%, there is slowdown compared to average historical growth rates 106.7%. The revenue growth dynamics is stable

Profitability: LTM EBITDA margin is negative, -17.1%. On average the margin is improving steadily. Gross margin is high, +91.6%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.1 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 1.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 201.1% higher than minimum and 0.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 5.3x by EV / Sales multiple , the company can be 70.1% overvalued

Key Financials (Download financials)

Ticker: ITCI
Share price, USD:  (0.0%)131.87
year average price 131.60  


year start price 127.01 2025-02-08

min close price 127.01 2025-02-08

max close price 131.92 2025-03-31

current price 131.87 2026-02-07
Common stocks: 94 324 300

Dividend Yield:  0.0%
EV / Sales: 17.9x
Margin (EBITDA LTM / Revenue): -17.1%
Fundamental value created in LTM:
Market Cap ($m): 12 439
Net Debt ($m): -290
EV (Enterprise Value): 12 149
Price to Book: 10.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-02-24businesswire.com

ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders

2025-02-24zacks.com

ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales

2025-02-21zacks.com

Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates

2025-02-21globenewswire.com

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

2025-01-14zacks.com

Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer

2025-01-14zacks.com

Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?

2025-01-13businesswire.com

Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders

2025-01-13zacks.com

ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz

2025-01-13investopedia.com

Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B

2025-01-13zacks.com

Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
filingDate 2025-03-20 2024-02-22 2023-03-01 2022-03-01 2021-02-25
acceptedDate 2025-03-20 17:29:09 2024-10-30 07:53:31 2024-08-07 07:55:30 2024-05-07 07:43:31 2024-02-22 07:42:52 2023-11-02 08:01:00 2023-08-03 07:44:08 2023-05-04 07:45:26 2023-03-01 07:46:11 2022-11-03 07:46:30 2022-03-01 07:46:27 2021-02-25 07:46:55
fiscalYear 2024 2023 2022 2021 2020
period FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 681M 175M 161M 145M 464M 126M 110M 95M 249M 72M 82M 23M
costOfRevenue 57M 15M 11M 10M 34M 9M 7M 7M 20M 6M 8M 2M
grossProfit 624M 160M 150M 135M 431M 117M 103M 88M 229M 66M 74M 21M
researchAndDevelopmentExpenses 236M 67M 56M 43M 180M 42M 50M 38M 135M 33M 89M 66M
generalAndAdministrativeExpenses 0 0 0 0 318M 0 0 0 273M 0 190M 150M
sellingAndMarketingExpenses 0 0 0 0 92M 0 0 0 86M 0 83M 36M
sellingGeneralAndAdministrativeExpenses 504M 132M 122M 113M 410M 105M 101M 99M 359M 88M 273M 186M
otherExpenses 0 -216 000 -56M 0 0 0 0 -575 000 -1M 0 -2M -282 226
operatingExpenses 741M 199M 178M 156M 590M 146M 150M 136M 492M 122M 359M 252M
costAndExpenses 798M 214M 189M 166M 624M 156M 157M 143M 513M 127M 367M 254M
netInterestIncome 43M 20M 7M 2M 4M
interestIncome 43M 13M 12M 6M 20M 5M 5M 4M 7M 2M 2M 4M
interestExpense 0 0 0 0 0 0 0 -4M 0 2M 0 0
depreciationAndAmortization 0 138 000 129 000 132 000 528 000 135 000 123 000 134 000 656 000 170 000 533 360 528 118
ebitda -117M -39M -28M -21M -159M -30M -47M -48M -263M -55M -285M -231M
ebit -117M -159M -264M -286M -231M
nonOperatingIncomeExcludingInterest 0 0 0 0 0
operatingIncome -117M -39M -28M -21M -159M -30M -47M -48M -264M -56M -286M -231M
totalOtherIncomeExpensesNet 43M 13M 12M 6M 20M 5M 5M 4M 7M 2M 2M 4M
incomeBeforeTax -74M -26M -16M -15M -139M -24M -43M -44M -256M -54M -284M -227M
incomeTaxExpense 473 000 374 000 57 000 359 000 636 000 43 000 135 000 10000 6000 1000 5631 13 513
netIncomeFromContinuingOperations -75M -140M -256M -284M -227M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncome -75M -26M -16M -15M -140M -24M -43M -44M -256M -54M -284M -227M
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -75M -140M -256M -284M -227M
eps -0.72 -0.25 -0.16 -0.16 -1.46 -0.25 -0.45 -0.46 -2.72 -0.57 -3.5 -3.23
epsDiluted -0.72 -1.46 -2.72 -3.5 -3.23
weightedAverageShsOut 103M 106M 104M 97M 96M 96M 96M 95M 94M 95M 81M 70M
weightedAverageShsOutDil 103M 106M 104M 97M 96M 96M 96M 95M 94M 95M 81M 70M
fillingDate 2024-10-30 2024-08-07 2024-05-07 2023-11-02 2023-08-03 2023-05-04 2022-11-03
calendarYear 2024 2024 2024 2023 2023 2023 2022
grossProfitRatio 0.913 0.93 0.932 0.927 0.935 0.929 0.919
ebitdaratio -0.221 -0.171 -0.144 -0.235 -0.428 -0.511 -0.772
operatingIncomeRatio -0.222 -0.172 -0.145 -0.236 -0.428 -0.511 -0.774
incomeBeforeTaxRatio -0.148 -0.1 -0.103 -0.192 -0.387 -0.465 -0.744
netIncomeRatio -0.15 -0.101 -0.105 -0.193 -0.388 -0.465 -0.745
epsdiluted -0.25 -0.16 -0.16 -0.25 -0.45 -0.46 -0.57
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
filingDate 2025-03-20 2024-02-22 2023-03-01 2022-03-01 2021-02-25
acceptedDate 2025-03-20 17:29:09 2024-10-30 07:53:31 2024-08-07 07:55:30 2024-05-07 07:43:31 2024-02-22 07:42:52 2023-11-02 08:01:00 2023-08-03 07:44:08 2023-05-04 07:45:26 2023-03-01 07:46:11 2022-11-03 07:46:30 2022-03-01 07:46:27 2021-02-25 07:46:55
fiscalYear 2024 2023 2022 2021 2020
period FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 307M 464M 695M 142M 148M 99M 142M 76M 149M 135M 92M 60M
shortTermInvestments 694M 542M 330M 336M 350M 394M 371M 463M 443M 493M 320M 597M
cashAndShortTermInvestments 1 001M 1 007M 1 025M 477M 498M 493M 513M 539M 592M 629M 412M 657M
netReceivables 167M 146M 146M 131M 114M 103M 96M 82M 75M 62M 20M 11M
accountsReceivables 167M 114M 75M 20M 11M
otherReceivables 0 0 0 0 0
inventory 26M 24M 20M 16M 12M 43M 42M 28M 24M 24M 8M 7M
prepaids 0 0 0 16M 14M
otherCurrentAssets 114M 96M 76M 66M 44M 62M 46M 56M 47M 46M 11M 1M
totalCurrentAssets 1 307M 1 272M 1 264M 691M 668M 702M 698M 706M 738M 760M 467M 691M
propertyPlantEquipmentNet 15M 16M 16M 14M 15M 15M 15M 16M 17M 22M 23M 26M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 45M 37M 40M 43M 46M 86 000 86 000 86 000 86 000 86 000 86 084 86 084
totalNonCurrentAssets 60M 53M 56M 57M 60M 15M 16M 16M 17M 22M 23M 26M
otherAssets 0 0 1 1 0 0 0 0 0 0 0 0
totalAssets 1 367M 1 324M 1 321M 747M 728M 718M 714M 722M 755M 782M 490M 717M
totalPayables 26M 11M 10M 9M 6M
accountPayables 26M 10M 18M 12M 11M 11M 8M 8M 10M 14M 9M 6M
otherPayables 0 0 0 0 0
accruedExpenses 0 27M 68M 38M 26M
shortTermDebt 4M 8M 8M 4M 0 4M 4M 4M 0 7M 0 0
capitalLeaseObligationsCurrent 0 4M 5M 7M 6M
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 175M 147M 136M 120M 81M 89M 81M 68M 0 56M -522 0
totalCurrentLiabilities 206M 166M 162M 135M 124M 103M 92M 80M 83M 77M 53M 37M
longTermDebt 13M 14M 14M 13M 0 14M 14M 15M 0 19M 18 675M 0
capitalLeaseObligationsNonCurrent 0 13M 15M 19M 24M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 0 0 0 0 -2M -18 675M 0
totalNonCurrentLiabilities 13M 14M 14M 13M 13M 14M 14M 15M 15M 19M 19M 24M
otherLiabilities 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 18M 18M 13M 17M 17M 18M 18M 20M 26M 25M 29M
totalLiabilities 218M 180M 176M 148M 137M 117M 107M 95M 99M 97M 72M 60M
treasuryStock 0 0 0 0 0
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 11 000 11 000 11 000 10000 10000 10000 10000 10000 9000 9000 8189 8046
retainedEarnings -1 692M -1 675M -1 649M -1 632M -1 617M -1 589M -1 564M -1 522M -1 477M -1 433M -1 221M -937M
additionalPaidInCapital 0 2 208M 2 138M 1 639M 1 593M
accumulatedOtherComprehensiveIncomeLoss 191 000 2M -668 000 -430 000 104 000 -1M -2M -3M -4M -5M -363 653 480 584
otherTotalStockholdersEquity 2 840M 0 0 0 0
totalStockholdersEquity 1 148M 1 145M 1 145M 599M 591M 601M 607M 628M 656M 685M 418M 657M
totalEquity 1 148M 1 145M 1 145M 599M 591M 601M 607M 628M 656M 685M 418M 657M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 367M 1 324M 1 321M 747M 728M 718M 714M 722M 755M 782M 490M 717M
totalInvestments 694M 542M 330M 336M 350M 394M 371M 463M 443M 493M 320M 597M
totalDebt 17M 18M 18M 16M 17M 17M 18M 18M 20M 26M 18 700M 29M
netDebt -290M -447M -677M -125M -131M -82M -124M -57M -129M -109M 18 608M -31M
fillingDate 2024-10-30 2024-08-07 2024-05-07 2023-11-02 2023-08-03 2023-05-04 2022-11-03
calendarYear 2024 2024 2024 2023 2023 2023 2022
othertotalStockholdersEquity 2 818M 2 794M 2 232M 2 191M 2 174M 2 152M 2 124M
totalLiabilitiesAndStockholdersEquity 1 324M 1 321M 747M 718M 714M 722M 782M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI ITCI
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
filingDate 2025-03-20 2024-02-22 2023-03-01 2022-03-01 2021-02-25
acceptedDate 2025-03-20 17:29:09 2024-10-30 07:53:31 2024-08-07 07:55:30 2024-05-07 07:43:31 2024-02-22 07:42:52 2023-11-02 08:01:00 2023-08-03 07:44:08 2023-05-04 07:45:26 2023-03-01 07:46:11 2022-11-03 07:46:30 2022-03-01 07:46:27 2021-02-25 07:46:55
fiscalYear 2024 2023 2022 2021 2020
period FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -75M -26M -16M -15M -140M -24M -43M -44M -256M -54M -284M -227M
depreciationAndAmortization -9M 138 000 129 000 132 000 528 000 135 000 123 000 134 000 656 000 170 000 533 360 528 118
deferredIncomeTax 0 0 0 0 0 -2M -2M 0 0 -1000 -4M -648 248
stockBasedCompensation 64M 17M 16M 14M 53M 14M 13M 10M 43M 12M 34M 24M
changeInWorkingCapital -54M -16M 2M -31M -30M -13M -5M -25M -58M -12M -6M -27M
accountsReceivables -52M 106 000 -15M -17M -39M -7M -14M -6M -55M -15M -9M -11M
inventory -15M -1M -2M -499 000 -26M -1M -14M -4M -16M 1M -891 741 -7M
accountsPayables 15M -7M 6M 80 000 1M 3M -708 000 -2M 2M 3M 3M -2M
otherWorkingCapital -1M -8M 13M -13M 35M -8M 23M 13M 11M -2M 740 843 -8M
otherNonCashItems 82 000 -2M 25M 29M -8M 24 000 23 000 -2M 537 000 253 000 178 534 214 103
netCashProvidedByOperatingActivities -73M -27M 542 000 -34M -124M -25M -37M -60M -270M -53M -260M -230M
investmentsInPropertyPlantAndEquipment -322 000 -696 000 -53 000 0 -269 000 -268 000 0 0 -778 000 -117 000 -325 738 -266 724
acquisitionsNet 0 0 0 0 0 20M 0 0 128M 0 -281M 480M
purchasesOfInvestments -740M -313M -89M -81M -415M -136M -66M -108M -759M -91M -225M -756M
salesMaturitiesOfInvestments 405M 104M 96M 97M 521M 116M 161M 92M 632M 197M 505M 276M
otherInvestingActivities 0 0 -128M 281M -480M
netCashProvidedByInvestingActivities -335M 106M -128M 280M -480M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 543M 0 434M 0 664M
netCommonStockIssuance 543M 0 434M 0 653M
commonStockIssuance 543M 18M 434M 12M 653M
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0
netPreferredStockIssuance 0 0 0 0 11M
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 24M 18M 21M 12M 71
netCashProvidedByFinancingActivities 568M 18M 455M 12M 664M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash 159M -229M 553M -8M -848 000 -43M 67M -73M 57M 58M 32M -46M
cashAtEndOfPeriod 309M 466M 695M 142M 150M 101M 144M 77M 150M 137M 94M 61M
cashAtBeginningOfPeriod 150M 695M 142M 150M 150M 144M 77M 150M 94M 79M 61M 108M
operatingCashFlow -73M -27M 542 000 -34M -124M -25M -37M -60M -270M -53M -260M -230M
capitalExpenditure -322 000 -696 000 -53 000 0 -269 000 -268 000 0 0 -778 000 -117 000 -325 738 -266 724
freeCashFlow -73M -27M 489 000 -34M -124M -26M -37M -60M -271M -53M -260M -230M
incomeTaxesPaid 2M 162 000 6000 6000 2000
interestPaid 0 0 0 0 0
fillingDate 2024-10-30 2024-08-07 2024-05-07 2023-11-02 2023-08-03 2023-05-04 2022-11-03
calendarYear 2024 2024 2024 2023 2023 2023 2022
otherInvestingActivites 0 8M 16M -20M 0 0 0
netCashUsedForInvestingActivites -209M 8M 16M -20M 95M -16M 106M
debtRepayment 0 0 0 0 0 0 0
commonStockIssued -12M 545M 10M 3M 0 4M 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites 7M 545M 10M 3M 0 0 6M
netCashUsedProvidedByFinancingActivities 7M 545M 10M 3M 9M 4M 6M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-08-07 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-03-01 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-09 ET (fiscal 2022 q2)
2022 q1
2022-05-10 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-02-21 09:00 ET
Intra-Cellular Therapies published news for 2024 q4
SEC form 8
2025-02-21 08:21 ET
Intra-Cellular Therapies reported for 2024 q4
SEC form 8
2025-02-21 08:21 ET
Intra-Cellular Therapies published news for 2024 q4
SEC form 10
2025-02-21 00:00 ET
Intra-Cellular Therapies published news for 2024 q4
SEC form 10
2024-10-30 07:53 ET
Intra-Cellular Therapies reported for 2024 q3
SEC form 8
2024-10-30 07:44 ET
Intra-Cellular Therapies reported for 2024 q3
SEC form 8
2024-10-30 07:44 ET
Intra-Cellular Therapies published news for 2024 q3
SEC form 10
2024-10-30 00:00 ET
Intra-Cellular Therapies reported for 2024 q3
SEC form 10
2024-08-07 07:55 ET
Intra-Cellular Therapies reported for 2024 q2
SEC form 8
2024-08-07 07:49 ET
Intra-Cellular Therapies published news for 2024 q2
SEC form 8
2024-08-07 07:49 ET
Intra-Cellular Therapies published news for 2024 q2
SEC form 8
2024-08-07 07:49 ET
Intra-Cellular Therapies published news for 2024 q2
SEC form 8
2024-08-07 07:49 ET
Intra-Cellular Therapies published news for 2024 q2
SEC form 8
2024-08-07 07:49 ET
Intra-Cellular Therapies published news for 2024 q2
SEC form 8
2024-08-07 07:49 ET
Intra-Cellular Therapies published news for 2024 q2
SEC form 8
2024-08-07 07:49 ET
Intra-Cellular Therapies reported for 2024 q2
SEC form 8
2024-08-07 07:49 ET
Intra-Cellular Therapies published news for 2024 q2
SEC form 10
2024-08-07 00:00 ET
Intra-Cellular Therapies published news for 2024 q2
SEC form 10
2024-05-07 07:43 ET
Intra-Cellular Therapies published news for 2024 q1
SEC form 8
2024-05-07 07:40 ET
Intra-Cellular Therapies reported for 2024 q1
SEC form 8
2024-05-07 07:40 ET
Intra-Cellular Therapies published news for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Intra-Cellular Therapies published news for 2024 q1
SEC form 8
2024-04-16 00:00 ET
Intra-Cellular Therapies published news for 2024 q1
SEC form 8
2024-04-16 00:00 ET
Intra-Cellular Therapies published news for 2024 q1
SEC form 8
2024-04-16 00:00 ET
Intra-Cellular Therapies published news for 2024 q1
SEC form 10
2024-02-22 07:42 ET
Intra-Cellular Therapies published news for 2023 q4
SEC form 8
2024-02-22 07:39 ET
Intra-Cellular Therapies published news for 2023 q4
SEC form 8
2024-02-22 07:39 ET
Intra-Cellular Therapies reported for 2023 q4
SEC form 10
2024-02-22 00:00 ET
Intra-Cellular Therapies published news for 2023 q4
SEC form 8
2023-11-02 08:01 ET
Intra-Cellular Therapies published news for 2023 q3
SEC form 10
2023-11-02 08:01 ET
Intra-Cellular Therapies reported for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Intra-Cellular Therapies published news for 2023 q3
SEC form 10
2023-08-03 07:44 ET
Intra-Cellular Therapies reported for 2023 q2
SEC form 6
2023-08-03 07:39 ET
Intra-Cellular Therapies published news for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Intra-Cellular Therapies published news for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Intra-Cellular Therapies published news for 2023 q2
SEC form 6
2023-06-23 16:15 ET
Intra-Cellular Therapies published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Intra-Cellular Therapies published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Intra-Cellular Therapies reported for 2023 q1
SEC form 6
2023-03-28 07:12 ET
Intra-Cellular Therapies published news for 2022 q4
SEC form 10
2023-03-01 07:46 ET
Intra-Cellular Therapies reported for 2022 q4
SEC form 6
2023-03-01 07:41 ET
Intra-Cellular Therapies published news for 2022 q4
SEC form 10
2023-03-01 00:00 ET
Intra-Cellular Therapies reported for 2022 q4
SEC form 8
2023-03-01 00:00 ET
Intra-Cellular Therapies reported for 2022 q4
SEC form 6
2023-01-09 17:13 ET
Intra-Cellular Therapies published news for 2022 q4
SEC form 6
2022-12-22 16:09 ET
Intra-Cellular Therapies published news for 2022 q3
SEC form 10
2022-11-03 07:46 ET
Intra-Cellular Therapies reported for 2022 q3
SEC form 6
2022-11-03 07:35 ET
Intra-Cellular Therapies published news for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Intra-Cellular Therapies reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Intra-Cellular Therapies reported for 2022 q3
SEC form 10
2022-08-09 07:47 ET
Intra-Cellular Therapies reported for 2022 q2
SEC form 6
2022-08-09 07:38 ET
Intra-Cellular Therapies published news for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Intra-Cellular Therapies published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Intra-Cellular Therapies reported for 2022 q2
SEC form 6
2022-06-13 17:01 ET
Intra-Cellular Therapies published news for 2022 q1
SEC form 10
2022-05-10 07:46 ET
Intra-Cellular Therapies reported for 2022 q1
SEC form 6
2022-05-10 07:37 ET
Intra-Cellular Therapies published news for 2022 q1
SEC form 8
2022-05-10 00:00 ET
Intra-Cellular Therapies reported for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Intra-Cellular Therapies reported for 2022 q1
SEC form 6
2022-04-25 07:12 ET
Intra-Cellular Therapies published news for 2022 q1
SEC form 6
2022-04-21 17:01 ET
Intra-Cellular Therapies published news for 2022 q1
SEC form 6
2022-04-21 16:52 ET
Intra-Cellular Therapies published news for 2022 q1
SEC form 6
2022-04-21 08:08 ET
Intra-Cellular Therapies published news for 2022 q1
SEC form 6
2022-03-01 07:49 ET
Intra-Cellular Therapies published news for 2021 q4
SEC form 10
2022-03-01 07:46 ET
Intra-Cellular Therapies published news for 2021 q4
SEC form 10
2022-03-01 00:00 ET
Intra-Cellular Therapies published news for 2021 q4
SEC form 8
2022-03-01 00:00 ET
Intra-Cellular Therapies published news for 2021 q4
SEC form 6
2022-01-07 16:12 ET
Intra-Cellular Therapies published news for 2021 q4
SEC form 6
2022-01-05 17:06 ET
Intra-Cellular Therapies published news for 2021 q4
SEC form 6
2022-01-05 16:58 ET
Intra-Cellular Therapies published news for 2021 q4
SEC form 8
2022-01-04 00:00 ET
Intra-Cellular Therapies published news for 2021 q4
SEC form 6
2022-01-03 17:38 ET
Intra-Cellular Therapies published news for 2021 q4
SEC form 6
2021-12-29 16:11 ET
Intra-Cellular Therapies published news for 2021 q3
SEC form 6
2021-12-20 07:04 ET
Intra-Cellular Therapies published news for 2021 q3
SEC form 6
2021-12-08 16:33 ET
Intra-Cellular Therapies published news for 2021 q3
SEC form 10
2021-11-09 07:53 ET
Intra-Cellular Therapies published news for 2021 q3
SEC form 6
2021-11-09 07:49 ET
Intra-Cellular Therapies published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Intra-Cellular Therapies published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Intra-Cellular Therapies published news for 2021 q3
SEC form 6
2021-08-09 07:37 ET
Intra-Cellular Therapies published news for 2021 q2
SEC form 10
2021-08-09 07:31 ET
Intra-Cellular Therapies published news for 2021 q2
SEC form 8
2021-08-09 00:00 ET
Intra-Cellular Therapies published news for 2021 q2
SEC form 10
2021-08-09 00:00 ET
Intra-Cellular Therapies published news for 2021 q2
SEC form 6
2021-06-22 16:30 ET
Intra-Cellular Therapies published news for 2021 q1
SEC form 6
2021-06-22 16:09 ET
Intra-Cellular Therapies published news for 2021 q1
SEC form 6
2021-05-10 07:37 ET
Intra-Cellular Therapies published news for 2021 q1
SEC form 10
2021-05-10 07:31 ET
Intra-Cellular Therapies published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
Intra-Cellular Therapies published news for 2021 q1
SEC form 8
2021-05-10 00:00 ET
Intra-Cellular Therapies published news for 2021 q1
SEC form 6
2021-05-03 07:42 ET
Intra-Cellular Therapies published news for 2021 q1
SEC form 6
2021-04-29 17:05 ET
Intra-Cellular Therapies published news for 2021 q1
SEC form 6
2021-04-19 17:28 ET
Intra-Cellular Therapies published news for 2021 q1
SEC form 6
2021-02-25 07:54 ET
Intra-Cellular Therapies published news for 2020 q4
SEC form 10
2021-02-25 07:46 ET
Intra-Cellular Therapies published news for 2020 q4
SEC form 6
2021-02-22 08:09 ET
Intra-Cellular Therapies published news for 2020 q4
SEC form 10
2020-11-09 07:45 ET
Intra-Cellular Therapies published news for 2020 q3
SEC form 6
2020-11-09 07:40 ET
Intra-Cellular Therapies published news for 2020 q3
SEC form 6
2020-10-28 16:02 ET
Intra-Cellular Therapies published news for 2020 q3
SEC form 6
2020-10-01 16:38 ET
Intra-Cellular Therapies published news for 2020 q3